Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker

Blood

Volumn 101, Issue 7, 2003, Pages 2557-2562

  Peng, Kah Whye ^a   Donovan, Kathleen A ^b   Schneider, Urs ^b   Cattaneo, Roberto ^b   Lust, John A ^b   Russell, Stephen J ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CD38 ANTIGEN; GLYCOPROTEIN; HEMAGGLUTININ; MEASLES VACCINE; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS RECEPTOR; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; CANCER ANTIBODY; CD38 PROTEIN, HUMAN; CD38 PROTEIN, MOUSE; HEMAGGLUTININ PROTEIN G, MEASLES VIRUS; IMMUNOGLOBULIN FRAGMENT; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; VIRUS HEMAGGLUTININ;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG SPECIFICITY; ENZYME DEGRADATION; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOBLOTTING; INFECTION RESISTANCE; INFECTION SENSITIVITY; MEASLES VIRUS; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR BINDING; SURVIVAL; TARGET CELL; TISSUE INJURY; TREATMENT OUTCOME; VIRAL GENE THERAPY; VIRUS ATTENUATION; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; BIOLOGICAL THERAPY; CELL CULTURE; CHEMISTRY; DISEASE MODEL; HAMSTER; IMMUNOLOGY; METHODOLOGY; MOUSE MUTANT; PATHOGENICITY; PHYSIOLOGY; PROTEIN ENGINEERING; SURVIVAL RATE; XENOGRAFT;

ADP-RIBOSYL CYCLASE; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, NEOPLASM; BIOLOGICAL THERAPY; CELLS, CULTURED; CRICETINAE; DISEASE MODELS, ANIMAL; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MEASLES VIRUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; MULTIPLE MYELOMA; PROTEIN ENGINEERING; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037769825     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-2195     Document Type: Article

References (32)

1. Kyle RA. Multiple myeloma: an odyssey of discovery. Br J Hematol. 2000;111:1035-1044.
2. Attal M, Harousseau JL. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol. 2001;38:226-230.
3. Bjorkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol. 2001;38:219-225.
4. Fassas A, Tricot G. Results of high dose treatment with autologous stem cell support in patients with multiple myeloma. Semin Hematol. 2001;38:231-242.
5. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med. 2000;7:781-787.
6. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98:2002-2007.
7. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 2002;6:527-531.
8. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62:4656-4662.
9. Schnieder U, Bullough F, Vongpunsawad S, Russell SJ, Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol. 2000;74:9928-9936.
10. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaeno R. Single chain antibody displayed on a recombinant measles virus confers entry through the tumor associated camino-embryonic antigen. J Virol. 2001;75:2087-2096.
11. Roscic-Mrkic B, Schwendener RA, Odermatt B, et al. Roles of macrophages in measles virus infection of genetically modified mice. J Virol. 2001;75:3343-3351.
12. Wild TF, Malvoisin E, Buckland R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol. 1991;72:439-442.
13. Dorig R, Marcil A, Chopra A, Richardson C. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75:295-305.
14. Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993;67:6025-6032.
15. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2001;406:893-897.
16. Hsu EC, Iorio C, Sarangi F, Khine AA, Richardson CD. CDw150 (SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology. 2001;279:9-21.
17. Manchester M, Eto DS, Valsamakis A, et al. Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol. 2000;74:3967-3974.
18. Jackson DG, Bell JI. Isolation of a cDNA-encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol. 1990;144:2811-2815.
19. Cathomen T, Buchholz CJ, Spielhofer P, Cattaneo R. Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region. Virology. 1995;214:628-632.
20. Singh M, Cattaneo R, Billeter MA. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol. 1999;73:4823-4828.
21. Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J. 1995;14:5773-5784.
22. Griffin D. Measles virus. In: Griffin D, Lamb R, Martin M, Roizman B, Straus S, eds. Field's Virology. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001;1401-1441.
23. Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications, and precaution recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1996;45:1-35.
24. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25:1-12.
25. Maloney DG, Donovan K, Hamblin TJ. Antibody therapy for treatment of multiple myeloma. Semin Hematol. 1999;36(1 suppl 3):30-33.
26. Bartz R, Brinckmann U, Dunster LM, Rima B, Ter Meulen V, Schneider-Schaulies J. Mapping amino acids of the measles virus hemagglutinin responsible for receptor (CD46) downregulation. Virology. 1996;224:334-337.
27. Lecouturier V, Fayolle J, Caballero M, et al. Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains. J Virol. 1996;70:4200-4204.
28. Patterson JB, Scheiflinger F, Manchester M, Yilma T, Oldstone MB. Structural and functional studies of the measles virus hemagglutinin; identification of a novel site required for CD46 interaction. Virology. 1999;256:142-151.
29. Schneider U, Von Messling V, Devaux P, Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J Virol. 2002;76:7460-7467.
30. Wickham TJ, Lee GM, Titus JA, et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol. 1997;71:7663-7669.
31. van Beusechem VW, Grill J, Mastenbroek DC, et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol. 2002;76:2753-2762.
32. Smith TA, Idamakanti N, Wright PM, et al. Heparan sulfate proteoglycans, and not CAR or integrins, are the major receptors for hepatic adenoviral transduction in vivo [abstract]. Mol Ther. 2002;5:S149.